<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BCD05341-5D48-43F1-A505-C169496883A1"><gtr:id>BCD05341-5D48-43F1-A505-C169496883A1</gtr:id><gtr:name>University of Hong Kong</gtr:name><gtr:address><gtr:line1>Pok Fu Lam Road</gtr:line1><gtr:line4>Hong Kong</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Hong Kong</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F7CB3F0-F626-4D76-9C43-28FB0DB6A61C"><gtr:id>2F7CB3F0-F626-4D76-9C43-28FB0DB6A61C</gtr:id><gtr:name>Takeda Pharmaceutical Company</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB"><gtr:id>6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB</gtr:id><gtr:name>University College London Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/84915200-8B36-4D78-B908-BE6E8F42B272"><gtr:id>84915200-8B36-4D78-B908-BE6E8F42B272</gtr:id><gtr:name>Medicines and Healthcare Regulatory Agency (MHRA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/743B0403-114A-4062-A04B-26B6E57DE502"><gtr:id>743B0403-114A-4062-A04B-26B6E57DE502</gtr:id><gtr:name>Columbia University</gtr:name><gtr:address><gtr:line1>Columbia University</gtr:line1><gtr:line2>2960 Broadway</gtr:line2><gtr:line4>New York</gtr:line4><gtr:line5>NY 10027-6902</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/85D77F48-0C7D-4555-8826-2133EE966981"><gtr:id>85D77F48-0C7D-4555-8826-2133EE966981</gtr:id><gtr:name>Drug Safety Research Unit</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D40A2786-39E9-42DD-96AB-920BAA1A0484"><gtr:id>D40A2786-39E9-42DD-96AB-920BAA1A0484</gtr:id><gtr:name>Base de Datos para la Investigaci?n en Farmacoepidemiolog?a en Atenci?n Primaria (BIFAP)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89E6D9CB-DAF8-40A2-A9EF-B330A5A7FC24"><gtr:id>89E6D9CB-DAF8-40A2-A9EF-B330A5A7FC24</gtr:id><gtr:name>Open University</gtr:name><gtr:address><gtr:line1>Walton Hall</gtr:line1><gtr:line2>Walton</gtr:line2><gtr:line4>Milton Keynes</gtr:line4><gtr:line5>Buckinghamshire</gtr:line5><gtr:postCode>MK7 6AA</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:department>Epidemiology and Population Health</gtr:department><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BCD05341-5D48-43F1-A505-C169496883A1"><gtr:id>BCD05341-5D48-43F1-A505-C169496883A1</gtr:id><gtr:name>University of Hong Kong</gtr:name><gtr:address><gtr:line1>Pok Fu Lam Road</gtr:line1><gtr:line4>Hong Kong</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Hong Kong</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F7CB3F0-F626-4D76-9C43-28FB0DB6A61C"><gtr:id>2F7CB3F0-F626-4D76-9C43-28FB0DB6A61C</gtr:id><gtr:name>Takeda Pharmaceutical Company</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB"><gtr:id>6020EDD4-B3F4-4D08-80DE-E387DD4EB8AB</gtr:id><gtr:name>University College London Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/84915200-8B36-4D78-B908-BE6E8F42B272"><gtr:id>84915200-8B36-4D78-B908-BE6E8F42B272</gtr:id><gtr:name>Medicines and Healthcare Regulatory Agency (MHRA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/743B0403-114A-4062-A04B-26B6E57DE502"><gtr:id>743B0403-114A-4062-A04B-26B6E57DE502</gtr:id><gtr:name>Columbia University</gtr:name><gtr:address><gtr:line1>Columbia University</gtr:line1><gtr:line2>2960 Broadway</gtr:line2><gtr:line4>New York</gtr:line4><gtr:line5>NY 10027-6902</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/85D77F48-0C7D-4555-8826-2133EE966981"><gtr:id>85D77F48-0C7D-4555-8826-2133EE966981</gtr:id><gtr:name>Drug Safety Research Unit</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D40A2786-39E9-42DD-96AB-920BAA1A0484"><gtr:id>D40A2786-39E9-42DD-96AB-920BAA1A0484</gtr:id><gtr:name>Base de Datos para la Investigaci?n en Farmacoepidemiolog?a en Atenci?n Primaria (BIFAP)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89E6D9CB-DAF8-40A2-A9EF-B330A5A7FC24"><gtr:id>89E6D9CB-DAF8-40A2-A9EF-B330A5A7FC24</gtr:id><gtr:name>Open University</gtr:name><gtr:address><gtr:line1>Walton Hall</gtr:line1><gtr:line2>Walton</gtr:line2><gtr:line4>Milton Keynes</gtr:line4><gtr:line5>Buckinghamshire</gtr:line5><gtr:postCode>MK7 6AA</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EC201DD8-0273-432E-A90A-E0E542A78151"><gtr:id>EC201DD8-0273-432E-A90A-E0E542A78151</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Douglas</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802403"><gtr:id>225822DF-42DA-489A-A3C1-BC2D3BAF194C</gtr:id><gtr:title>Developing methodologies for use in observational studies of drug effects using computerised clinical data.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0802403</gtr:grantReference><gtr:abstractText>The safety of medicines can be difficult to investigate and often the only possibility is to conduct observational studies to see whether people receiving a drug are more likely to experience a side effect than people who do not receive the drug. Recently more and more of these studies have been done and frequently their results have been of major public health importance (e.g. the lack of association between MMR vaccine and autism). It is important that the results of these studies are reliable, and yet their underpinning methodologies are subject to many possible biases. I plan to investigate some of these methodologies and explore their biases, with the objective of increasing the reliability of drug safety studies. This will be achieved through at least four studies using an electronic database of anonymised patient medical records. The studies will investigate possible links between SSRI antidepressants and cerebral haemorrhage, tiotropium (a treatment for chronic obstructive pulmonary disease) and stroke, ezetimibe (a lipid lowering agent) and cancer and glitazone antidiabetics and myocardial infarction. This programme of research will therefore answer questions directly related to the safety of four drugs/drug classes and will improve methodological approaches to drug safety studies in the future.</gtr:abstractText><gtr:technicalSummary>The efficacy of a medicine is established by the time it becomes marketed. However, the possible harms associated with a drug are usually less well understood. Randomised controlled trials to assess side effects are often impractical as they may need to be unfeasibly large or could be unethical. Observational studies therefore offer an ideal practical method for investigating drug safety issues, and in recent years the number of such studies has increased. Much research in this area is done using anonymised patient information from large primary care databases such as the General Practice Research Database (GPRD). Over the last three years I have gained substantial experience in using the GPRD to answer questions about the safety of medicines. Recent advances in data quality and linkage offer even greater opportunities for research, but better methodologies are needed to take full advantage. I propose the following programme of research in order to improve approaches to using primary care data for drug safety studies:

AIMS: 
 Further develop strategies for using primary care data. In particular focusing on diagnostic validity, the impact of consultation frequency and distinguishing prevalent from incident diagnoses.
 Explore the utility and limitations of the self-controlled case series method. Specifically I will investigate the impact of time varying confounders, situations where the occurrence of an outcome of interest affects the length of the observation period and instances where the likelihood of exposure is dependent on the presence or absence of the outcome of interest.

OBJECTIVES:
 To improve on existing methods and establish optimal methodologies for conducting drug safety studies.

METHODOLOGY
 I plan to achieve these aims by conducting four drug safety studies examining the associations between: SSRI antidepressants and cerebral haemorrhage; ezetimibe and cancer; tiotropium and stroke; and glitazones and myocardial infarction. I will use the self controlled case series method, comparing results with other study designs, such as case control and cohort methods and using external validatory data from randomised clinical trials. Collaborative input will be provided by the Medical Statistics Unit of LSHTM and the Department of Statistics at the Open University

SCIENTIFIC/MEDICAL OPPORTUNITIES
 The current regulatory environment demands more observational studies of drug effects. Patients and prescribers rightly expect investigators to produce reliable answers to questions about the safety of a drug and robust methodologies are therefore needed to ensure confidence in the outcome of drug safety studies.</gtr:technicalSummary><gtr:fund><gtr:end>2015-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>432285</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Takeda Pharmaceutical Company</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Takeda</gtr:description><gtr:id>055C52F6-474B-4D46-8890-562BD208F608</gtr:id><gtr:impact>Not funded. Expertise includes statistics, epidemiology, drug regulation, primary care</gtr:impact><gtr:outcomeId>BHXBZX6wPri-1</gtr:outcomeId><gtr:partnerContribution>Contributed to application for MRC Case Studentship</gtr:partnerContribution><gtr:piContribution>Led application for an MRC Case Studentship</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Farr Pharmacoepi</gtr:description><gtr:id>105B84E1-BD5C-45C2-B262-3536148E0070</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545ba269537f70.35970263-1</gtr:outcomeId><gtr:partnerContribution>All partners are engaged with definining aims, objectives and deliverables for the project</gtr:partnerContribution><gtr:piContribution>I am leading a collaborative bid for funding across three of the recently established Farr Institutes, to develop better methodology to define drug exposures using electronic healthcare records, and to apply this to currently relevant clinical research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medicines and Healthcare Regulatory Agency (MHRA)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Vigilance &amp; Risk Management</gtr:department><gtr:description>SSRI and stroke</gtr:description><gtr:id>B43C3DE7-6E95-4BF7-B02A-8DF91314D2CD</gtr:id><gtr:impact>Br J Clin Pharmacol. 2011 Jan;71(1):116-20. doi: 10.1111/j.1365-2125.2010.03797.x.
The use of antidepressants and the risk of haemorrhagic stroke: a nested case control study.
Douglas I, Smeeth L, Irvine D.</gtr:impact><gtr:outcomeId>Mw5bA6GYo4C-1</gtr:outcomeId><gtr:partnerContribution>Data provision and collaboration for a study now completed</gtr:partnerContribution><gtr:piContribution>I was involved with the study design, carried out all analysis and wrote the manuscript for this study</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Epidemiology and Health Care</gtr:department><gtr:description>clopidogrel</gtr:description><gtr:id>3CB9A623-95FA-408C-815C-837ADC2E343B</gtr:id><gtr:impact>BMJ. 2012 Jul 10;345:e4388. doi: 10.1136/bmj.e4388.
Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs.
Douglas IJ, Evans SJ, Hingorani AD, Grosso AM, Timmis A, Hemingway H, Smeeth L.

Disciplines represented: cardiology, epidemiology, general practice, pharmacy</gtr:impact><gtr:outcomeId>W2r1tKkzRAh-1</gtr:outcomeId><gtr:partnerContribution>Providing specific clinical expertisePharmacy expertise</gtr:partnerContribution><gtr:piContribution>I led and conducted an observational study to assess the clinical implications of a theoretical interaction between clopidogrel and proton pump inhibitors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hong Kong</gtr:collaboratingOrganisation><gtr:country>Hong Kong, Special Administrative Region of China</gtr:country><gtr:department>Department of Pharmacology and Pharmacy</gtr:department><gtr:description>Hong Kong Uni</gtr:description><gtr:id>89A2B6FE-146E-45F0-9EB4-4FD3C8DC488C</gtr:id><gtr:impact>Ongoing. Multidisciplinary team with statistics, pharmacy, pharmacology and pharmacoepidemiology expertise. Resulted in 1 publication (in press; journal Paediatrics), and 2 successful funding applications</gtr:impact><gtr:outcomeId>dmm7ayWvC7z-1</gtr:outcomeId><gtr:partnerContribution>Leading study planning for Hong Kong studies, obtaining data, data analysis</gtr:partnerContribution><gtr:piContribution>Input to study design and analysis plan for two planned studies. One has secured funding, another is pending. Hosted 3 visitors from Hong Kong in 2014 to learn about UK primary care data and to conduct a series of pharmacoepi studies supervised by me</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>IMI funded PhD studentship (Amgen)</gtr:description><gtr:id>7360B331-EE14-4B95-925E-0EB8D6E30D91</gtr:id><gtr:impact>Publication (first author Brauer 2014); Publication (first author Brauer, 2011); conference presentation at ICPE Chicago 2011, ICPE Barcelona 2012, ICPE Montreal 2013. Disciplines represented - statistics, epidemiology, general practice</gtr:impact><gtr:outcomeId>g3QST7jZv1o-1</gtr:outcomeId><gtr:partnerContribution>Data and expertise provided</gtr:partnerContribution><gtr:piContribution>I am primary supervisor for this PhD studentship which is directly aligned with my own research priorities</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Columbia University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Huntington's</gtr:description><gtr:id>AF6DEA5F-2E3A-41AA-ACAF-409825C2068C</gtr:id><gtr:impact>Publications: 23482661, 23558730. Multidisciplinary team with public health, statistics, epidemiology, Huntington's disease, primary care expertise</gtr:impact><gtr:outcomeId>hXvnyzcac9r-1</gtr:outcomeId><gtr:partnerContribution>Input to planning, design, analysis, interpretation and manuscript drafting for all elements</gtr:partnerContribution><gtr:piContribution>Led the design and analysis of one aspect of the project. Obtained data for all aspects. Input to planning, design, analysis, interpretation and manuscript drafting for all elements</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Obesity</gtr:description><gtr:id>60985A2D-2AF5-4B2B-A6B2-EC616B85270C</gtr:id><gtr:impact>Ongoing: expertise includes epidemiology, statistics, primary care, bariatrics. Results presented at Euroepi Aarhus 2013; ICPE Montreal 2013, ICPE Taipei 2014. PLoS Medicine paper, Int J Obesity paper, BJCP paper.</gtr:impact><gtr:outcomeId>NY4xE8uUvCu-1</gtr:outcomeId><gtr:partnerContribution>Input to study design, analysis plan, interpretation and drafting</gtr:partnerContribution><gtr:piContribution>Study design, obtaining data, analysis, intepretation and drafting manuscripts, applying for further research funding</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Huntington's</gtr:description><gtr:id>B9365A47-0F04-469A-A1E4-FCEA44EF89D4</gtr:id><gtr:impact>Publications: 23482661, 23558730. Multidisciplinary team with public health, statistics, epidemiology, Huntington's disease, primary care expertise</gtr:impact><gtr:outcomeId>hXvnyzcac9r-2</gtr:outcomeId><gtr:partnerContribution>Input to planning, design, analysis, interpretation and manuscript drafting for all elements</gtr:partnerContribution><gtr:piContribution>Led the design and analysis of one aspect of the project. Obtained data for all aspects. Input to planning, design, analysis, interpretation and manuscript drafting for all elements</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>Glitazones</gtr:description><gtr:id>3E2EB672-35FE-47D5-8F17-31551E2AD609</gtr:id><gtr:impact>Study completed and submitted for publication; results presented at ICPE Taipei, 2014. Expertise in epidemiology, general practice, statistics, diabetes, Parkinson's disease</gtr:impact><gtr:outcomeId>jjXkzSJaWqZ-1</gtr:outcomeId><gtr:partnerContribution>Assistance with drafting the protocol, from expertise in diabetes and pre-clinical Parkinson's disease</gtr:partnerContribution><gtr:piContribution>Led the planning of the study and application for funding. The study will investigate whether the glitazone antidiabetics prevent the development of Parkinson's disease</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Base de Datos para la Investigaci?n en Farmacoepidemiolog?a en Atenci?n Primaria (BIFAP)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>IMI BIFAP</gtr:description><gtr:id>753A453E-B683-4395-AD4D-76060138AED7</gtr:id><gtr:impact>Ongoing.</gtr:impact><gtr:outcomeId>WxZxHsYygSj-1</gtr:outcomeId><gtr:partnerContribution>Data provision, analysis</gtr:partnerContribution><gtr:piContribution>Hosting a visitor to learn how to use the self-controlled case series, contributing expertise to study design, analysis, and interpretation.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Pfizer self controlled case series</gtr:description><gtr:id>D1A7E61C-3EE8-4D5D-8E00-01308E713136</gtr:id><gtr:impact>In progress</gtr:impact><gtr:outcomeId>54639c4b2ea180.33832105-1</gtr:outcomeId><gtr:partnerContribution>Pfizer had the idea for the study, obtained the data and will do the analyses</gtr:partnerContribution><gtr:piContribution>Initial discussions for a collaboration on the use of the self-controlled case series for signal identification using electornic health records. I have contributed to the design of a study and will comment further as the study progresses</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Open University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Mathematics and Statistics</gtr:department><gtr:description>Self controlled case series</gtr:description><gtr:id>B523A453-0F40-4FC3-BBC0-B6DDABF6D4E7</gtr:id><gtr:impact>Farrington et al paper (2011). Collaboration involves statisticians, epidemiologists and a eneral practitioner.</gtr:impact><gtr:outcomeId>phtgFKsLwaK-1</gtr:outcomeId><gtr:partnerContribution>Through this collaboration I am able to drawn on the statistical expertise of the department in applying novel methodology to my own research</gtr:partnerContribution><gtr:piContribution>I directly contributed to the development of a modified verion of the self-controlled case series by providing real world data from my own work (antipsychotics and stroke), thus allowing the method to be extended beyond simulation stage</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Glitazones</gtr:description><gtr:id>23D3E0D7-AB96-4D1C-B419-C311B97C5420</gtr:id><gtr:impact>Study completed and submitted for publication; results presented at ICPE Taipei, 2014. Expertise in epidemiology, general practice, statistics, diabetes, Parkinson's disease</gtr:impact><gtr:outcomeId>jjXkzSJaWqZ-2</gtr:outcomeId><gtr:partnerContribution>Assistance with drafting the protocol, from expertise in diabetes and pre-clinical Parkinson's disease</gtr:partnerContribution><gtr:piContribution>Led the planning of the study and application for funding. The study will investigate whether the glitazone antidiabetics prevent the development of Parkinson's disease</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Drug Safety Research Unit</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DSRU</gtr:description><gtr:id>AE20C12C-7E35-4E9F-8CA2-23C3653A1C8F</gtr:id><gtr:impact>None to date: Disciplines represented, Medicine, epidemiology, medical statistics</gtr:impact><gtr:outcomeId>J9ADZ7Mo4qS-1</gtr:outcomeId><gtr:partnerContribution>Primary research question, obtaining data, data analysis, drafting reports</gtr:partnerContribution><gtr:piContribution>Expertise in the use of electronic health records to measure the effects of drugs, specifically use of the self-controlled case series</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>Innovative Medicines Initiative (IMI)</gtr:department><gtr:description>IMI Protect funded PhD studentships (GPRD)</gtr:description><gtr:id>5D7EB575-14D0-4A0E-8BBF-4A94BE729A53</gtr:id><gtr:impact>Both students continuing research projects. Output presented at conferences : EuropEpi, Aarus 2013, ICPE Montreal 2013, ICPE Barcelona 2012. Disciplines: statistics, epidemiology, general practice. Publications; first author Wing, 2014</gtr:impact><gtr:outcomeId>sjLuZaLmghW-1</gtr:outcomeId><gtr:partnerContribution>GPRD partners contribute both data and expertise</gtr:partnerContribution><gtr:piContribution>I am directly supervising two PhD students carrying out research directly aligned with the aims of my fellowship to improve methodologies for obervational studies of drug effects</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Pharmacovigilance and Traceability</gtr:department><gtr:description>IMI funded PhD studentship (Amgen)</gtr:description><gtr:id>B6EACC50-6033-4DA2-850E-E85A84AD00B5</gtr:id><gtr:impact>Publication (first author Brauer 2014); Publication (first author Brauer, 2011); conference presentation at ICPE Chicago 2011, ICPE Barcelona 2012, ICPE Montreal 2013. Disciplines represented - statistics, epidemiology, general practice</gtr:impact><gtr:outcomeId>g3QST7jZv1o-2</gtr:outcomeId><gtr:partnerContribution>Data and expertise provided</gtr:partnerContribution><gtr:piContribution>I am primary supervisor for this PhD studentship which is directly aligned with my own research priorities</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Pharmacy</gtr:department><gtr:description>clopidogrel</gtr:description><gtr:id>1DC946C3-60DF-4AB5-8D60-01800A09FF18</gtr:id><gtr:impact>BMJ. 2012 Jul 10;345:e4388. doi: 10.1136/bmj.e4388.
Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs.
Douglas IJ, Evans SJ, Hingorani AD, Grosso AM, Timmis A, Hemingway H, Smeeth L.

Disciplines represented: cardiology, epidemiology, general practice, pharmacy</gtr:impact><gtr:outcomeId>W2r1tKkzRAh-2</gtr:outcomeId><gtr:partnerContribution>Providing specific clinical expertisePharmacy expertise</gtr:partnerContribution><gtr:piContribution>I led and conducted an observational study to assess the clinical implications of a theoretical interaction between clopidogrel and proton pump inhibitors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Epidemiology</gtr:department><gtr:description>GSK</gtr:description><gtr:id>80D68461-7363-41D2-9599-0A80A46C74C6</gtr:id><gtr:impact>None to date. Expertise in epidemiology and medical statistics</gtr:impact><gtr:outcomeId>PUWDDfvbbqx-1</gtr:outcomeId><gtr:partnerContribution>Obtaining data, data analysis, co-supervision of students and research fellow</gtr:partnerContribution><gtr:piContribution>Expertise in the use of the self-controlled case series study. We are developing research projects involving both PhD students and a research fellow to pursue methodological advances in the study of drug effects using real world data. We have now appointed 2 PhD studnets to look at different aspects of methodological pharmacoepidemiology.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medicines and Healthcare Regulatory Agency (MHRA)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>General Practice Research Database (GPRD)</gtr:department><gtr:description>IMI Protect funded PhD studentships (GPRD)</gtr:description><gtr:id>6B6895E6-9D5B-4E65-8C91-3606F5DE1D83</gtr:id><gtr:impact>Both students continuing research projects. Output presented at conferences : EuropEpi, Aarus 2013, ICPE Montreal 2013, ICPE Barcelona 2012. Disciplines: statistics, epidemiology, general practice. Publications; first author Wing, 2014</gtr:impact><gtr:outcomeId>sjLuZaLmghW-2</gtr:outcomeId><gtr:partnerContribution>GPRD partners contribute both data and expertise</gtr:partnerContribution><gtr:piContribution>I am directly supervising two PhD students carrying out research directly aligned with the aims of my fellowship to improve methodologies for obervational studies of drug effects</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Farr Pharmacoepi</gtr:description><gtr:id>1451DB44-9533-46BE-B7DB-08FC2BEF3BD4</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>545ba269537f70.35970263-2</gtr:outcomeId><gtr:partnerContribution>All partners are engaged with definining aims, objectives and deliverables for the project</gtr:partnerContribution><gtr:piContribution>I am leading a collaborative bid for funding across three of the recently established Farr Institutes, to develop better methodology to define drug exposures using electronic healthcare records, and to apply this to currently relevant clinical research</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>GSK talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>076B047D-2E21-4071-8FAE-E38E1B492B21</gtr:id><gtr:impact>~30 drug industry epidemiologists in a single company were keen to hear more about techniques I have used (propensity scores and the self controlled case series) as they are considering these methods for their research activities.

Stronger ties with industrial contacts who are keen to take advice from me going forward.</gtr:impact><gtr:outcomeId>UA3pz6Jbq7H</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>495446</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Methodology</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M013278/1</gtr:fundingRef><gtr:id>8FE6F58A-563B-4575-930D-9E340A4CF2D6</gtr:id><gtr:outcomeId>56d808da00adb8.31537675</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>56144</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RNIB Research Funding</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Royal National Institute for Blind People</gtr:fundingOrg><gtr:id>07DC8F1C-D4B0-4784-89E4-AA4AB43D5EC7</gtr:id><gtr:outcomeId>5458e1a8a24d07.16490740</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sir Henry Wellcome Postdoctoral Fellowship (supervisor)</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>107340/Z/15/Z</gtr:fundingRef><gtr:id>EF5C20B5-201A-4DAB-AD50-271A7DDA45E5</gtr:id><gtr:outcomeId>56d807f6c69df6.50272131</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>238859</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC population health scientist fellowship (supervisor)</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M014649/1</gtr:fundingRef><gtr:id>DDB5CCBA-CB57-407D-BF3C-707608D5E51A</gtr:id><gtr:outcomeId>56d807797b6c69.57533639</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>213938</gtr:amountPounds><gtr:country>China, People's Republic of</gtr:country><gtr:currCode>HKD</gtr:currCode><gtr:currCountryCode>Hong Kong</gtr:currCountryCode><gtr:currLang>zh_HK</gtr:currLang><gtr:description>Pharmacoepidemiology of oral anticoagulation agents - a comparison of dabigatran exilate, warfarin and dual-antiplatelet therapy in patients with atrial fibrillation</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Research Grants Council Hong Kong</gtr:fundingOrg><gtr:id>29FB5373-F6F8-4B7A-8A33-CE5ECC6502FD</gtr:id><gtr:outcomeId>545ce4f4bb22e5.73850524</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>357632</gtr:amountPounds><gtr:country>China, People's Republic of</gtr:country><gtr:currCode>HKD</gtr:currCode><gtr:currCountryCode>Hong Kong</gtr:currCountryCode><gtr:currLang>zh_HK</gtr:currLang><gtr:description>ADHD Treatments and Hospital Accident and emergency attendance aNalysis (ATHAN</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Research Grants Council Hong Kong</gtr:fundingOrg><gtr:id>53F621E1-78E0-4975-B78E-6AA638A3EB67</gtr:id><gtr:outcomeId>545ce60450f5b7.36167195</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>341261</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Innovative Medicines Initiative</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>0065068D-42D0-4BFA-A542-3934C0AAE25C</gtr:id><gtr:outcomeId>TH5FuawodV70</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>74930</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Michael J Fox Foundation Rapid Response Award</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:id>CE650B17-7862-4D01-A505-2CCF240CE625</gtr:id><gtr:outcomeId>gy9kmkc6tBz</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Primary care data use workshop</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AA0872B0-0448-4C60-8D47-8C298B1129F7</gtr:id><gtr:outcomeId>Pz7ddQ7ZLva</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Membership of Pharmacovigilance Expert Advisory Group</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>4B9CB515-CD05-4207-B9E3-691AF8B1EEFC</gtr:id><gtr:impact>Improvement in the methods used to investigate adverse drug effects of public health importance. Improvements in the committments for post-marketing safety assessment made by pharmaceutical companies at the time of drug licensing.</gtr:impact><gtr:outcomeId>ThjzTHrAvGm</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EMA Workshop</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>7301BA4E-EB93-4BE5-802E-3EBD036706EC</gtr:id><gtr:impact>Contributed to workshop for guidelines on drug effectiveness research using observational data</gtr:impact><gtr:outcomeId>Kqw5krugfkz</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Hong Kong training</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>04976AF4-B207-46B8-81EB-6CF71FA69672</gtr:id><gtr:outcomeId>545b64391574c6.13513165</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Short courses in pharmacoepidemiology</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>60CDF197-E18A-487A-9E2F-0EDAE9B987AE</gtr:id><gtr:impact>By bringing together experts in the field of pharmaoepidemiology from LSHTM, the GPRD, MHRA and other organisations I established a new advanced short course in pharmacoepidemiology at LSHTM. This ran for the first year in 2010, and is complimentary to the well establisehd pharmacoepidemiology and pharmacovigilance short course run by LSHTM. I am course organiser for both courses, and the student body this year was from Europe, North America, Africa and Asia. These courses are an important capacity building resource for people working in the area of drug safety in industry, regulatory authorities and increasingly academic institutions. 
I am now leading the development of a distance learning version of the LSHTM Cert in Pharmacoepidemiology and Pharmacovigilance</gtr:impact><gtr:outcomeId>pWfxm5kLWjF</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MHRA Training</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A6BB3E91-23CF-416A-9544-7DE03C346F48</gtr:id><gtr:impact>Tailor made training designed, and delivered for MHRA requiring expertise in understanding pharmacoepidemiology in order to assess drug licensing and safety issues</gtr:impact><gtr:outcomeId>aJ3Q4Qmuhyq</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Euroepi Training</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>A7A906F4-ECFC-49D9-B8F9-EA25425D60FD</gtr:id><gtr:outcomeId>545b64782898a5.43941088</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>I have acquired a source of linked data containing the primary care records and highly accurate information on myocardial ischaemia events for patients receiving antiplatelet medication. Such linked data has only just been made available for research and will lead to vast improvements in the accuracy of outcome ascertainment and hence the validity of research findings.</gtr:description><gtr:id>EE36E25A-CE5F-4726-8D97-0FAE6740A75C</gtr:id><gtr:impact>This work has been presented at an international conference (ICPE, Chicago 2011), and submitted for publication</gtr:impact><gtr:outcomeId>YPv5nbPLxSR</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Linked data - GPRD + MINAP</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7E539CEA-7FA8-457B-A735-58E9A75977A8</gtr:id><gtr:title>Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57fafa65e0f7e155a757529b74e3cf9c"><gtr:id>57fafa65e0f7e155a757529b74e3cf9c</gtr:id><gtr:otherNames>Beau-Lejdstrom R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>58c9509fdc31d0.76066086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B0AA045-F431-43FB-A0EB-2821574E0AA9</gtr:id><gtr:title>Cardiovascular outcomes associated with use of clarithromycin: population based study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56a18ff69bed042292b5ab38b5bafea2"><gtr:id>56a18ff69bed042292b5ab38b5bafea2</gtr:id><gtr:otherNames>Wong AY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>58c9509f7b4f71.63616061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>539FDEB4-D344-4965-B8CC-5137A6EEC0B8</gtr:id><gtr:title>The use of antidepressants and the risk of haemorrhagic stroke: a nested case control study.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3650ed17f36da854817baf6c9078fcc8"><gtr:id>3650ed17f36da854817baf6c9078fcc8</gtr:id><gtr:otherNames>Douglas I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>mfQuebYeN6q</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21388522-E50F-47B9-BE85-B955E238AC42</gtr:id><gtr:title>Bariatric Surgery in the United Kingdom: A Cohort Study of Weight Loss and Clinical Outcomes in Routine Clinical Care.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcb05cf77e5fc2081789614f1c91c026"><gtr:id>dcb05cf77e5fc2081789614f1c91c026</gtr:id><gtr:otherNames>Douglas IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>56d80306896e94.90655814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05EFD3A9-027E-40D4-BD50-677219F969E4</gtr:id><gtr:title>Signal Detection for Recently Approved Products: Adapting and Evaluating Self-Controlled Case Series Method Using a US Claims and UK Electronic Medical Records Database.</gtr:title><gtr:parentPublicationTitle>Drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2161a7b82e55ae2cc0a43abe8c874d5d"><gtr:id>2161a7b82e55ae2cc0a43abe8c874d5d</gtr:id><gtr:otherNames>Zhou X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0114-5916</gtr:issn><gtr:outcomeId>5aa0fa12487f06.28870003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5D65D7A-B19E-4E36-9F2C-86F63FA08946</gtr:id><gtr:title>Validation of asthma recording in electronic health records: protocol for a systematic review.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87354aeca9afe118fe8f13b26dac3a7e"><gtr:id>87354aeca9afe118fe8f13b26dac3a7e</gtr:id><gtr:otherNames>Nissen F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5aa0fa13e6d440.28473521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC6F0C6C-6092-4DAB-97D3-5828E0D883EA</gtr:id><gtr:title>Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study.</gtr:title><gtr:parentPublicationTitle>European heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb11728f38b6df70e2f5c6be235cbd5"><gtr:id>ccb11728f38b6df70e2f5c6be235cbd5</gtr:id><gtr:otherNames>Brauer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0195-668X</gtr:issn><gtr:outcomeId>545b622c5f4c73.40112725</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>877FA375-43C8-4EDD-B726-BAC4BDD29A7B</gtr:id><gtr:title>Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: A systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>European journal of preventive cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02f611de01f3eae9244b905bfe36189a"><gtr:id>02f611de01f3eae9244b905bfe36189a</gtr:id><gtr:otherNames>Sinnott SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2047-4873</gtr:issn><gtr:outcomeId>58c9509e79d734.65993401</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93C8C276-B6C8-4CE7-84C0-2BC4BAD73F4F</gtr:id><gtr:title>The Prevalence of Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Neuroepidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/745563f85829dbaa1965e22c06d1b78b"><gtr:id>745563f85829dbaa1965e22c06d1b78b</gtr:id><gtr:otherNames>Rawlins MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0251-5350</gtr:issn><gtr:outcomeId>56d8030729ccc4.61901525</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6106092-7877-4A0A-B18B-5EC6473DCDB2</gtr:id><gtr:title>Prevalence of antibiotic use: a comparison across various European health care data sources.</gtr:title><gtr:parentPublicationTitle>Pharmacoepidemiology and drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb11728f38b6df70e2f5c6be235cbd5"><gtr:id>ccb11728f38b6df70e2f5c6be235cbd5</gtr:id><gtr:otherNames>Brauer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1053-8569</gtr:issn><gtr:outcomeId>56d80306327f44.65176442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47417EDB-24C8-459E-82A6-4BD006AA2303</gtr:id><gtr:title>Cutting feedback in Bayesian regression adjustment for the propensity score.</gtr:title><gtr:parentPublicationTitle>The international journal of biostatistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bced5f9c4b4fb163d2c5383636d5e70"><gtr:id>8bced5f9c4b4fb163d2c5383636d5e70</gtr:id><gtr:otherNames>McCandless LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1557-4679</gtr:issn><gtr:outcomeId>E5h98qyRPNo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BB8FFA3-C559-4758-99CE-E529BD5D4A1A</gtr:id><gtr:title>Trends for prevalence and incidence of resistant hypertension: population based cohort study in the UK 1995-2015.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02f611de01f3eae9244b905bfe36189a"><gtr:id>02f611de01f3eae9244b905bfe36189a</gtr:id><gtr:otherNames>Sinnott SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5aa0fa131c5959.25516942</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7082962F-75B7-4F84-A448-10B3B01D6705</gtr:id><gtr:title>Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e0d4e7f8ede732817caf54d3c97d372"><gtr:id>9e0d4e7f8ede732817caf54d3c97d372</gtr:id><gtr:otherNames>Evans SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_15358_28_23482661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DD670A0-5F0E-425A-940A-5DC8C266A903</gtr:id><gtr:title>Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe.</gtr:title><gtr:parentPublicationTitle>Pharmacoepidemiology and drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb11728f38b6df70e2f5c6be235cbd5"><gtr:id>ccb11728f38b6df70e2f5c6be235cbd5</gtr:id><gtr:otherNames>Brauer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1053-8569</gtr:issn><gtr:outcomeId>58c9509edaadf1.95479810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD581A1F-96DD-434D-BAAF-7245AEF92E0B</gtr:id><gtr:title>Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0.</gtr:title><gtr:parentPublicationTitle>Pharmacoepidemiology and drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edd7f819ca15ef5aa89e34af0c2d8d8f"><gtr:id>edd7f819ca15ef5aa89e34af0c2d8d8f</gtr:id><gtr:otherNames>Wang SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1053-8569</gtr:issn><gtr:outcomeId>5aa0fa134583c5.01755262</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D9595AE-5C11-4937-92DD-046375A9A8CF</gtr:id><gtr:title>Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines.</gtr:title><gtr:parentPublicationTitle>Pharmacoepidemiology and drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81d11184c2efe520cec7eadc15fa01e9"><gtr:id>81d11184c2efe520cec7eadc15fa01e9</gtr:id><gtr:otherNames>Requena G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1053-8569</gtr:issn><gtr:outcomeId>56d803053d5802.71333375</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6FAAC282-63C9-4DAE-912A-58535EAC2E3F</gtr:id><gtr:title>Validation of asthma recording in the Clinical Practice Research Datalink (CPRD).</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87354aeca9afe118fe8f13b26dac3a7e"><gtr:id>87354aeca9afe118fe8f13b26dac3a7e</gtr:id><gtr:otherNames>Nissen F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5aa0fa1397b6f4.52908289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9E9758C-138C-4EAC-81C1-3FF3142D0D7D</gtr:id><gtr:title>Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcb05cf77e5fc2081789614f1c91c026"><gtr:id>dcb05cf77e5fc2081789614f1c91c026</gtr:id><gtr:otherNames>Douglas IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_15358_28_23585064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAF52D86-B51A-4B06-A6C7-0A7A287976EF</gtr:id><gtr:title>Population trends in the 10-year incidence and prevalence of diabetic retinopathy in the UK: a cohort study in the Clinical Practice Research Datalink 2004-2014.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0932dcd014438629afa5aaa305271b53"><gtr:id>0932dcd014438629afa5aaa305271b53</gtr:id><gtr:otherNames>Mathur R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>58c9509e4dd1a0.17042662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8928AB11-8FBE-48FF-82CE-0C49689D568F</gtr:id><gtr:title>The association between Parkinson's disease and anti-epilepsy drug carbamazepine: a case-control study using the UK General Practice Research Database.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378d7be43e98c70cfd7fe1118e625d3f"><gtr:id>378d7be43e98c70cfd7fe1118e625d3f</gtr:id><gtr:otherNames>Skow A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>pm_15358_28_23432592</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CAC46AD-00CD-4FBA-BD83-BA9CF20F775C</gtr:id><gtr:title>Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcb05cf77e5fc2081789614f1c91c026"><gtr:id>dcb05cf77e5fc2081789614f1c91c026</gtr:id><gtr:otherNames>Douglas IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_15358_28_22782731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E5B12B4-8417-4B3B-94F9-D4F731A6E369</gtr:id><gtr:title>Juvenile Huntington's disease: a population-based study using the General Practice Research Database.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3650ed17f36da854817baf6c9078fcc8"><gtr:id>3650ed17f36da854817baf6c9078fcc8</gtr:id><gtr:otherNames>Douglas I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_15358_28_23558730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BA70226-A858-4AC2-AF22-984F7CFEBCF3</gtr:id><gtr:title>Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34d5e471b7205d01395a0714811445bc"><gtr:id>34d5e471b7205d01395a0714811445bc</gtr:id><gtr:otherNames>Root AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>58c9509f30ca83.93790078</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B55C470-81D2-4703-8E39-C9ADF874EC2E</gtr:id><gtr:title>Acute kidney injury and infections in patients taking antihypertensive drugs: a self-controlled case series analysis.</gtr:title><gtr:parentPublicationTitle>Clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/940c562854d9ccc63378c0718b552b2c"><gtr:id>940c562854d9ccc63378c0718b552b2c</gtr:id><gtr:otherNames>Mansfield KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1179-1349</gtr:issn><gtr:outcomeId>5aa0fa121d2a79.03627029</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EECAF8BD-19D7-4F73-A143-5C10EF0F0D6C</gtr:id><gtr:title>Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45fedb8ee1637fead70c220f52216105"><gtr:id>45fedb8ee1637fead70c220f52216105</gtr:id><gtr:otherNames>Wing K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>5aa0fa136ac4c1.10498763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CC0D577-5E31-4D36-A263-323966DB4FA4</gtr:id><gtr:title>Inhaled tiotropium bromide and risk of stroke.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fc5d19ec428c6bf3c650b0c41026b28"><gtr:id>6fc5d19ec428c6bf3c650b0c41026b28</gtr:id><gtr:otherNames>Grosso A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>PaWetyowj4e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10DA0542-D505-4B14-8D65-2989187A8E4D</gtr:id><gtr:title>The association between antipsychotic agents and the risk of myocardial infarction: a systematic review.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb11728f38b6df70e2f5c6be235cbd5"><gtr:id>ccb11728f38b6df70e2f5c6be235cbd5</gtr:id><gtr:otherNames>Brauer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>VYDd2esPw9t</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F899F651-A208-4E13-BB10-1C9F5C4D657A</gtr:id><gtr:title>Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink.</gtr:title><gtr:parentPublicationTitle>BMC cardiovascular disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b23fd19382c7941f8f9c887d00a4dd3"><gtr:id>4b23fd19382c7941f8f9c887d00a4dd3</gtr:id><gtr:otherNames>Macedo AF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2261</gtr:issn><gtr:outcomeId>545b622c36ce05.52162699</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88E6B933-FCBE-4138-88E8-E52D8E297F01</gtr:id><gtr:title>The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcb05cf77e5fc2081789614f1c91c026"><gtr:id>dcb05cf77e5fc2081789614f1c91c026</gtr:id><gtr:otherNames>Douglas IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>56d80305113f08.49721080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4A59F19-9692-472A-A1B0-39FAF4C500E3</gtr:id><gtr:title>Optimising case detection within UK electronic health records: use of multiple linked databases for detecting liver injury.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45fedb8ee1637fead70c220f52216105"><gtr:id>45fedb8ee1637fead70c220f52216105</gtr:id><gtr:otherNames>Wing K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>585d3b0a269cf0.61181209</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF5213C0-8ABC-476D-9255-2AF66A4CC95A</gtr:id><gtr:title>The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>International journal of obesity (2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8370df7b6bc85787096ddee70abdcca5"><gtr:id>8370df7b6bc85787096ddee70abdcca5</gtr:id><gtr:otherNames>Hayes JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0307-0565</gtr:issn><gtr:outcomeId>56d803059debb4.36978420</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75CDE045-BF65-4CE2-AB81-89896DE58AFE</gtr:id><gtr:title>Self-Controlled Case Series Analysis With Event-Dependent Observation Periods</gtr:title><gtr:parentPublicationTitle>Journal of the American Statistical Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1497bd05ab3434f81cdc7bb6664da1d1"><gtr:id>1497bd05ab3434f81cdc7bb6664da1d1</gtr:id><gtr:otherNames>Farrington C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>rbb4QfKGfys</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E96537F0-BEA9-4B4A-B7B0-47EF84410250</gtr:id><gtr:title>Representativeness and optimal use of body mass index (BMI) in the UK Clinical Practice Research Datalink (CPRD).</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51b27dff90b7776e265d03044cb6699d"><gtr:id>51b27dff90b7776e265d03044cb6699d</gtr:id><gtr:otherNames>Bhaskaran K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_15358_28_24038008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99347191-4D13-44FD-98F5-F454797D7D1C</gtr:id><gtr:title>Angiotensin receptor blockers and risk of dementia: cohort study in UK Clinical Practice Research Datalink.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9cd79c9c0a410602ea1dc68249c82de"><gtr:id>f9cd79c9c0a410602ea1dc68249c82de</gtr:id><gtr:otherNames>Goh KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>545b622cdeb478.92536905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD8E38AB-0376-474E-BFA4-999A63D640FA</gtr:id><gtr:title>The identification of incident cancers in UK primary care databases: a systematic review.</gtr:title><gtr:parentPublicationTitle>Pharmacoepidemiology and drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/358529de7af21d6bf830ec1fabe9d31c"><gtr:id>358529de7af21d6bf830ec1fabe9d31c</gtr:id><gtr:otherNames>Ra?opa M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1053-8569</gtr:issn><gtr:outcomeId>56d8037843b9a9.42869729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9211123E-1C97-4137-8DAC-904FE5250649</gtr:id><gtr:title>Association between oral fluoroquinolones and seizures: A self-controlled case series study.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5ca755d62daf9b888b2d8855a7b2df6"><gtr:id>c5ca755d62daf9b888b2d8855a7b2df6</gtr:id><gtr:otherNames>Chui CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>58c9509f5a5a69.64974476</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D19C2169-A4DB-47BD-A74F-7C67B2D804A7</gtr:id><gtr:title>Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb11728f38b6df70e2f5c6be235cbd5"><gtr:id>ccb11728f38b6df70e2f5c6be235cbd5</gtr:id><gtr:otherNames>Brauer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>56d803065ddef3.86166606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02A21326-668D-424C-AF48-0A0D1527802D</gtr:id><gtr:title>Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb86fa9acdbda47c911fd5c8f2bfa4cb"><gtr:id>bb86fa9acdbda47c911fd5c8f2bfa4cb</gtr:id><gtr:otherNames>Crellin E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5aa0fa11e04557.86829134</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AA63DFD-DBA0-4FE7-92C2-8287720E352B</gtr:id><gtr:title>Acute Cardiovascular Events after Herpes Zoster: A Self-Controlled Case Series Analysis in Vaccinated and Unvaccinated Older Residents of the United States.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8dd0917c9a0d920aa3756482dbf39816"><gtr:id>8dd0917c9a0d920aa3756482dbf39816</gtr:id><gtr:otherNames>Minassian C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>56d80305cc1620.08014225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6A3DD1B-2D1C-4301-9B06-9811A29AE616</gtr:id><gtr:title>Self controlled case series methods: an alternative to standard epidemiological study designs.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c554cbefbcfedffe9c54704cfb7440a"><gtr:id>7c554cbefbcfedffe9c54704cfb7440a</gtr:id><gtr:otherNames>Petersen I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>58c9509eb24563.40674022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFD8EC3D-EAA2-4BF5-8DFE-67B41BA06FFB</gtr:id><gtr:title>The risk of acute liver injury among users of antibiotic medications: a comparison of case-only studies.</gtr:title><gtr:parentPublicationTitle>Pharmacoepidemiology and drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb11728f38b6df70e2f5c6be235cbd5"><gtr:id>ccb11728f38b6df70e2f5c6be235cbd5</gtr:id><gtr:otherNames>Brauer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1053-8569</gtr:issn><gtr:outcomeId>56d803060924a3.39025322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0AFA7D8-8576-489D-A6DE-A50B89459FC2</gtr:id><gtr:title>Red blood cell transfusion and mortality in trauma patients: risk-stratified analysis of an observational study.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfd8c267b78cf5a764bc4ee22e4f0a1e"><gtr:id>cfd8c267b78cf5a764bc4ee22e4f0a1e</gtr:id><gtr:otherNames>Perel P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>545b622c86c907.69213773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F5A0C0D-7606-4E5F-B168-4777C9F6A624</gtr:id><gtr:title>Methylphenidate and the risk of trauma.</gtr:title><gtr:parentPublicationTitle>Pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/570db3d1478a3a66a7239649bfe75e3f"><gtr:id>570db3d1478a3a66a7239649bfe75e3f</gtr:id><gtr:otherNames>Man KK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0031-4005</gtr:issn><gtr:outcomeId>56d80306c529d7.20446943</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>780EEFB6-8E2C-4298-82F5-061DA01F52BF</gtr:id><gtr:title>Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: A population based cohort.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/555aedc1c0a8cad1524997adb12aa924"><gtr:id>555aedc1c0a8cad1524997adb12aa924</gtr:id><gtr:otherNames>Yates TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>5aa0fa12c7f980.65178291</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>798EB0E9-7595-4D53-ACC5-787D34979A03</gtr:id><gtr:title>Cardiovascular Outcomes after a Respiratory Tract Infection among Adults with Non-Cystic Fibrosis Bronchiectasis: A General Population-based Study.</gtr:title><gtr:parentPublicationTitle>Annals of the American Thoracic Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ddeb4b0d25d1d8a565eddbd6154bbd6"><gtr:id>4ddeb4b0d25d1d8a565eddbd6154bbd6</gtr:id><gtr:otherNames>Navaratnam V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2325-6621</gtr:issn><gtr:outcomeId>5aa0fa1271e698.32731471</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C70ED1A-0DA9-4602-B00B-927135573247</gtr:id><gtr:title>Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/172d15fb65c47960baf70805a7156aca"><gtr:id>172d15fb65c47960baf70805a7156aca</gtr:id><gtr:otherNames>Matthews A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>58c9509f9f7f12.27697923</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA52B4EE-CE87-47F7-85FE-9B989649AFAA</gtr:id><gtr:title>Investigating the assumptions of the self-controlled case series method.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c26558a1abc6432dde9934f05987b9c5"><gtr:id>c26558a1abc6432dde9934f05987b9c5</gtr:id><gtr:otherNames>Whitaker HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>5aa0fa12ea7181.20206519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB3B5F0E-BDEE-4214-8323-0B032C251DF0</gtr:id><gtr:title>BMI and risk of dementia in two million people over two decades: a retrospective cohort study</gtr:title><gtr:parentPublicationTitle>The Lancet Diabetes &amp; Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fba754ef387452e6c7f6d1eadf430c24"><gtr:id>fba754ef387452e6c7f6d1eadf430c24</gtr:id><gtr:otherNames>Qizilbash N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d803056e8267.28663435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7FB1014-7984-45BD-8D4C-AA3F24978410</gtr:id><gtr:title>Case-only designs for studying the association of antidepressants and hip or femur fracture.</gtr:title><gtr:parentPublicationTitle>Pharmacoepidemiology and drug safety</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5db58ed54035b3b4a25eba88c63c8588"><gtr:id>5db58ed54035b3b4a25eba88c63c8588</gtr:id><gtr:otherNames>de Groot MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1053-8569</gtr:issn><gtr:outcomeId>58c9509f0d2098.62566748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3352C622-B8B8-49BE-8FAF-0C3B0A551FC6</gtr:id><gtr:title>Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45fedb8ee1637fead70c220f52216105"><gtr:id>45fedb8ee1637fead70c220f52216105</gtr:id><gtr:otherNames>Wing K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>545b622caf6185.04302181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87CDFC79-272D-4664-8AD8-39ACB6C83AB6</gtr:id><gtr:title>Propensity score analysis with partially observed covariates: How should multiple imputation be used?</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8a0cd7ea00fdb0624c168b25ae61a0f"><gtr:id>f8a0cd7ea00fdb0624c168b25ae61a0f</gtr:id><gtr:otherNames>Leyrat C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>5aa0fa13ba9552.87188408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F4668FB-539A-47F5-B71B-4CC92D3D6D9B</gtr:id><gtr:title>Incidence of adult Huntington's disease in the UK: a UK-based primary care study and a systematic review.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72f33eb26c0be7cf921722580f404c3c"><gtr:id>72f33eb26c0be7cf921722580f404c3c</gtr:id><gtr:otherNames>Wexler NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>56dfea754c5231.33619314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>176F871F-BB14-437F-9D78-6094BF4D8422</gtr:id><gtr:title>Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5&amp;middot;24 million UK adults.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51b27dff90b7776e265d03044cb6699d"><gtr:id>51b27dff90b7776e265d03044cb6699d</gtr:id><gtr:otherNames>Bhaskaran K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>545b622c105a62.76369412</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BF08311-5379-4388-8F53-E33B4FF3EDAE</gtr:id><gtr:title>Effect of statin treatment on short term mortality after pneumonia episode: cohort study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3650ed17f36da854817baf6c9078fcc8"><gtr:id>3650ed17f36da854817baf6c9078fcc8</gtr:id><gtr:otherNames>Douglas I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>FLSoYiX1bKT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6061D50B-3954-4513-A77A-A7528516B0BD</gtr:id><gtr:title>Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51b27dff90b7776e265d03044cb6699d"><gtr:id>51b27dff90b7776e265d03044cb6699d</gtr:id><gtr:otherNames>Bhaskaran K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_15358_28_22531797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5689FF54-0351-4BA9-9EA8-3B3C67A50C50</gtr:id><gtr:title>The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcb05cf77e5fc2081789614f1c91c026"><gtr:id>dcb05cf77e5fc2081789614f1c91c026</gtr:id><gtr:otherNames>Douglas IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>WYXXMQMYZfi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48985C6B-3E8E-4829-9CCF-857AA87314D6</gtr:id><gtr:title>Validation of asthma recording in electronic health records: a systematic review.</gtr:title><gtr:parentPublicationTitle>Clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87354aeca9afe118fe8f13b26dac3a7e"><gtr:id>87354aeca9afe118fe8f13b26dac3a7e</gtr:id><gtr:otherNames>Nissen F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1179-1349</gtr:issn><gtr:outcomeId>5aa0fa129c3e42.16247589</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802403</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>